Kenvue stock (US49177J1025): Analysts lower targets to $19 amid uncertainty

Analysts recently cut Kenvue price targets by $1 to around $19, reflecting higher discount rates and revenue growth adjustments, while the stock offers a 4.72% dividend yield.

Kenvue, the consumer health spin-off from Johnson & Johnson, faces adjusted analyst expectations as several firms lowered price targets by $1 to $19 per share. This reflects slightly higher discount rate assumptions and modestly different revenue growth projections, according to Simply Wall St as of May 2026. Ratings remain clustered around Hold and Neutral.

The stock traded at around $22 in recent sessions on the NYSE, with a market cap of $33.76 billion and P/E ratio of 15.16, per MarketBeat as of May 2026. Kenvue also appears in Zacks' list of top income stocks for May 11, 2026, buoyed by a 5.5% upward revision in current-year earnings consensus over the last 60 days.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kenvue
• Sector/industry: Consumer Staples / Household Products
• Headquarters/country: United States
• Core markets: US, global consumer health
• Key revenue drivers: Skin care, OTC medicines, baby care
• Home exchange/listing venue: NYSE (KVUE)
• Trading currency: USD

Kenvue: core business model

Kenvue operates as a pure-play consumer health company, focusing on self-care brands in skin health, beauty, essential health, and pain relief. Formed via a 2023 spin-off from Johnson & Johnson, it manages iconic products like Tylenol, Neutrogena, and Listerine. The model emphasizes innovation in over-the-counter medicines and personal care, with 22,000 employees supporting global distribution.

Headquartered in Skillman, New Jersey, Kenvue targets everyday consumer needs, generating revenue through a portfolio of trusted brands. Its separation allowed focused capital allocation toward growth in high-margin categories, as detailed on MarketBeat as of May 2026.

Main revenue and product drivers for Kenvue

Key drivers include skin and beauty care (e.g., Neutrogena), baby care (Johnson's), oral care (Listerine), and OTC pharmaceuticals (Tylenol, Motrin). The company reported a 3.2% year-over-year revenue increase, signaling steady demand in consumer health, per MarketBeat forecast as of May 2026. Dividend yield stands at 4.72%, appealing for income-focused US investors.

Over-the-counter medicines form a core pillar, bolstered by US market dominance where consumer health spending ties to economic resilience. Efficiency initiatives optimize costs while funding growth, as noted in recent coverage.

Industry trends and competitive position

The consumer health sector benefits from aging populations and self-care trends, with Kenvue competing against Procter & Gamble and Haleon. Its NYSE listing provides US investors direct exposure to stable staples amid volatility. A 4.72% yield outperforms many peers, per MarketBeat data.

Why Kenvue matters for US investors

Listed on NYSE, Kenvue offers US retail investors a defensive play in consumer staples, with heavy reliance on the US market for revenue. Brands like Tylenol hold strong shelf space in American pharmacies, linking performance to domestic spending patterns.

Conclusion

Kenvue maintains a solid position in consumer health with strong brands and a high dividend yield, though recent analyst target cuts to $19 signal caution on growth and rates. US investors value its NYSE access and income stream. Market dynamics will shape near-term performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.